欧洲着手制定高血压管理指南

2012-04-09 范伟伟(编译) 医学论坛网

  2012年3月7日在线发表于《高血压杂志》(J Hypertens)的一篇报道指出,欧洲高血压学会和欧洲心脏病学会已开始准备编写动脉高血压管理联合指南(第3版)。编写者关注了新版英国国立卫生与临床优化研究所(NICE)指南,以了解在制定指南建议时整理证据工作的困难。新版NICE指南在以下2大方面有重要改变:即应用动态血压诊断高血压,初始治疗抗高血压药物的的选择(减少利尿剂的使用,推荐

  2012年3月7日在线发表于《高血压杂志》(J Hypertens)的一篇报道指出,欧洲高血压学会和欧洲心脏病学会已开始准备编写动脉高血压管理联合指南(第3版)。编写者关注了新版英国国立卫生与临床优化研究所(NICE)指南,以了解在制定指南建议时整理证据工作的困难。新版NICE指南在以下2大方面有重要改变:即应用动态血压诊断高血压,初始治疗抗高血压药物的的选择(减少利尿剂的使用,推荐氯噻酮和吲达帕胺的使用)。NICE指南在这些建议的制定方面更倾向于意见,而并非证据。该报道指出,对证据和临床显著疗效的追求无可厚非,然而这种“好方法”并非屡试不爽。

      链接:Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management - is nice always good?
 



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1946121, encodeId=da2f1946121a1, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Feb 11 14:52:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936245, encodeId=e84c19362459d, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sun Aug 12 12:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338879, encodeId=07ac13388e9b7, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Wed Apr 11 04:52:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344283, encodeId=3434134428320, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Apr 11 04:52:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1946121, encodeId=da2f1946121a1, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Feb 11 14:52:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936245, encodeId=e84c19362459d, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sun Aug 12 12:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338879, encodeId=07ac13388e9b7, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Wed Apr 11 04:52:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344283, encodeId=3434134428320, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Apr 11 04:52:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1946121, encodeId=da2f1946121a1, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Feb 11 14:52:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936245, encodeId=e84c19362459d, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sun Aug 12 12:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338879, encodeId=07ac13388e9b7, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Wed Apr 11 04:52:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344283, encodeId=3434134428320, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Apr 11 04:52:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1946121, encodeId=da2f1946121a1, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Feb 11 14:52:00 CST 2013, time=2013-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936245, encodeId=e84c19362459d, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Sun Aug 12 12:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338879, encodeId=07ac13388e9b7, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Wed Apr 11 04:52:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344283, encodeId=3434134428320, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Apr 11 04:52:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]

相关资讯

真实世界数据——老年多支病变 CABG长期生存率高于PCI

  3月27日,由美国心脏病学会基金会(ACCF)和胸外科医师学会(STS)联合开展的一项纳入近19万例65岁以上多支病变患者的大型观察性研究ASCERT表明,冠状动脉旁路移植术(CABG)较经皮冠状动脉介入( PCI)治疗拥有更高的长期(4年)生存率。论文同天在线发表于《新英格兰医学杂志》(N Engl J Med)。   研究纳入ACCF C

现场心外科支持对PCI结局的影响

  纳入23585例患者的随机对照CPORT-E研究显示,无现场心外科支持的医院行非急诊PCI治疗,患者短期(6周全因死亡)与长期(9个月严重不良心脏事件)预后不劣于有现场心外科支持者。     

肺动脉异物患者仁济医院获救

    “好!上钩啦!”   “稳住,慢一点,别让它逃走!”   “哈!终于钓上来了!”   这样的场景不是在小河、池塘边,而是发生在医院的手术台,到底是怎么一回事呢?   近日,上海交通大学医学院附属仁济医院血管外科叶猛医生经双侧股静脉,运用导管技术,操作圈套抓捕器,成功“钓”出了患者肺动脉内长达20多厘米的异物。   患者,男性,64岁,为多发性骨髓瘤患者,自行剪断了右侧

极化液未能阻止ACS进展

  IMMEDIATE研究显示,可疑急性冠脉综合征患者中,静脉予极化液(30%葡萄糖、50单位胰岛素、80 mEq KCL/l)未减少进展为心肌梗死的几率。     

超声下加压治疗股动脉瘤安全有效

  中山大学附属第一医院血管外科的一项研究表明,超声引导下加压治疗医源性股动脉假性动脉瘤安全、易于操作,有较好的临床疗效。该论文发表在2012年第4期《中华外科杂志》。   研究人员回顾性分析了2004年至2010年间42例医源性股动脉假性动脉瘤患者的治疗经过,其中男性28例,女性14例;平均年龄52岁。患者在股动脉穿刺后出现腹股沟区搏动性肿块,经多普勒超声确诊为股动脉假性动脉瘤。在超声引

快速床边基因检测指导个体化抗血小板治疗

  RAPID GENE研究探讨了一项快速床边基因检测的临床应用,成功确定了CYP2C19*2 等位基因,这是一个常见的基因变异,与接受经皮冠状动脉介入治疗(PCI)及氯吡格雷治疗的患者主要不良事件增加有关。此研究发表于《柳叶刀》(Lancet)杂志。   许多患者接受双联抗血小板治疗,仍然具有心血管不良事件高风险。这种持续的风险与血小板高活性有关,其特征是血小板P2Y12受